Prevention of Contrast Induced Nephropathy by Erythropoietin
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This ia a prospective, randomized, double blind, placebo controlled trial. patients schedule
for primary PCI or elective PCI will randomly allocated to receive either a single dose of
EPO (Recormon, Roche, Epoetin beta) or saline intravenously before PCI.
The investigators assume that the incidence rate of CIN will be significantly lower in the
EPO group compared to placebo. In addition, EPO administration will result in a decrease of
infarct size.